Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Related Keywords

United States ,Palo Alto ,Texas ,Americans ,Jason Ehrlich ,Charlesc Wykoff ,Development Officer ,Prnewswire Kodiak Sciences Inc ,Kodiak Sciences Inc ,Nasdaq ,Non Proliferative Diabetic Retinopathy ,Retina Consultants ,Chief Medical ,Antibody Biopolymer Conjugate ,Trial Identifier ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,